Last updated: February 20, 2026
What is the Drug NDC 00078-0456?
NDC 00078-0456 corresponds to Avastin (bevacizumab). It is a monoclonal antibody used in oncology treatments, primarily for colorectal, lung, ovarian, renal cell, and glioblastoma cancers. The drug is produced by Genentech, a Roche subsidiary.
Market Overview
Current Market Size
The global bevacizumab market was valued at approximately USD 8.3 billion in 2022. It is projected to reach USD 12.2 billion by 2028, growing at a compound annual growth rate (CAGR) of 6.7% (Fortune Business Insights, 2022). The U.S. accounts for a significant share, nearly 45%, driven by high cancer incidence rates and strong reimbursement policies.
Key Players
| Company |
Market Share (2022) |
Notable Attributes |
| Genentech/Roche |
55% |
First-to-market, broad indication use |
| Amgen |
20% |
Biosimilar competitor |
| Samsung Bioepis |
10% |
Biosimilar, approved in multiple markets |
Regulatory Status
- Approved for use in metastatic colorectal, non-small cell lung, glioblastoma, ovarian, cervical, and renal cell carcinomas.
- Biosimilars approved in the U.S. include Mvasi (amgen), Zirabev (Samsung Bioepis), and others.
Reimbursement Landscape
Medicare and private insurers in U.S. provide varied coverage, often influencing pricing strategies and market penetration. Price negotiations and formulary placements significantly impact revenue.
Pricing Landscape
List Prices and Reimbursement
| Product |
Price per vial (USD) |
Indications |
Market Availability |
| Original Avastin |
USD 2,300 - 2,600 |
Multiple oncology indications |
Available in US, EU, Asia |
| Mvasi (biosimilar) |
USD 1,600 - 1,800 |
Same indications as Avastin |
US, EU, competitive biosimilar markets |
| Zirabev (biosimilar) |
USD 1,700 |
Similar indications |
US, EU |
Price Trends
- The original Avastin has experienced price erosion (~10-15%) annually since biosimilar approval in 2019.
- Biosimilar entry has driven overall market prices downward, with discounts of roughly 30-40% compared to the originator.
Key Market Drivers and Constraints
Drivers
- Rising incidence of cancer globally.
- Expanding indications, including in hepatocellular carcinoma and gastric cancers.
- Increasing biosimilar adoption, reducing treatment costs.
- Strong R&D pipeline exploring novel combinations and new indications.
Constraints
- Patent expiry of Avastin in certain markets (e.g., EU 2021).
- Regulatory hurdles for biosimilar acceptance.
- Reimbursement challenges in developing markets.
Price Projections (2023-2028)
| Year |
Average Price per Vial (USD) |
Notes |
| 2023 |
USD 1,600 - 1,800 |
Biosimilar market expanding, originator stabilizing |
| 2024 |
USD 1,550 - 1,750 |
Slight price erosion expected |
| 2025 |
USD 1,500 - 1,700 |
Biosimilar competition intensifies |
| 2026 |
USD 1,450 - 1,650 |
Market consolidates further |
| 2027 |
USD 1,400 - 1,600 |
New biosimilars may enter with further discounts |
| 2028 |
USD 1,350 - 1,550 |
Potential price stabilization at lower levels |
Market Risks
- Regulatory delays in biosimilar approvals.
- Patent litigation prolonging exclusivity.
- Shifts in clinical guidelines affecting utilization rates.
- Price controls in some jurisdictions limiting revenue growth.
Opportunities
- Increasing use of combination therapies.
- Expansion into new indications.
- Market penetration in emerging economies.
- Development of next-generation biosimilars with lower production costs.
Key Takeaways
- The original Avastin market is shrinking due to biosimilar competition, with prices decreasing by roughly 10-15% annually.
- Biosimilars are entering multiple markets, leading to a complex price environment.
- Future revenue growth depends on expanding indications, biosimilar uptake, and market penetration in emerging regions.
- Price per vial is projected to decline gradually, reaching approximately USD 1,350 - 1,550 by 2028.
- The overall market is expected to grow at a CAGR of approximately 6.7%, driven by increasing cancer burden and new indications.
FAQs
-
What are the primary competitors to NDC 00078-0456?
Biosimilars like Mvasi and Zirabev compete directly. Several biosimilars are approved globally, reducing originator revenues.
-
How does biosimilar entry affect pricing?
Biosimilars typically reduce prices by 30-40%, leading to overall market price erosion and increased treatment affordability.
-
What factors influence future price trends?
Regulatory approvals, patent litigation, biosimilar adoption rates, and healthcare policy changes.
-
What is the forecasted market growth rate?
The global bevacizumab market is expected to grow at approximately 6.7% CAGR through 2028.
-
Are there regional differences in pricing?
Yes. Prices tend to be higher in the U.S. and Europe due to reimbursement policies, while emerging markets often see lower prices.
References
[1] Fortune Business Insights. (2022). Bevacizumab market size, share & industry analysis. https://www.fortunebusinessinsights.com
[2] IQVIA. (2022). Global Oncology Biosimilars Market Report.
[3] U.S. Food and Drug Administration. (2021). Biosimilar approvals and guidance.
[4] European Medicines Agency. (2021). Biosimilar medicines overview.
[5] National Cancer Institute. (2022). Cancer statistics.
